Gastrointestinal Disorder Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets

GBI Research, June 2010, Pages: 143

“Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets”, provides in-depth analysis of the unmet needs, drivers and barriers that affect the global gastrointestinal disorder therapeutics market. It analyzes the markets for gastrointestinal disorder therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

The authors find that the gastrointestinal disorder therapeutics market will decline during the period 2009-2016. This decline is primarily driven by the negative growth of gastroesophageal reflux disease (GERD) therapeutics market which is attributed to loss of drug patents and entry of generics. However, other key gastrointestinal disorders such as crohn’s disease and irritable bowels syndrome therapeutics market will continue to grow due to strong late stage pipeline that will address the unmet needs. The global gastrointestinal disorder therapeutics market is a highly fragmented market and big players are facing stiff competition. The forthcoming patent expiries of major drugs have increased the competition, driving the consolidation further. The increasing pressure has also driven companies to enter into licensing agreements. This allows companies to expand product portfolio and improve their competitive positions in the market.

Scope

The scope of this report includes:

- Annualized market data for the gastrointestinal disorder therapeutics market from 2001 to 2009, forecast forward to 2016

- Analysis of the leading therapeutic segments. These include crohn’s disease, ulcerative colitis, irritable bowel syndrome, and gastroesophageal reflux disease.

- Analysis of the gastrointestinal disorder therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France,
Italy, Spain, and Japan

- Market characterization of the gastrointestinal disorder therapeutics market including market size, annual cost of therapy, and treatment usage patterns

- Key drivers and barriers that have a significant impact on the market

- Coverage of pipeline molecules in various phases of drug development

- Competitive benchmarking of leading companies. The key companies studied in this report are AstraZeneca, Takeda pharmaceutical company Ltd., Eisai pharmaceuticals Nycomed, Pfizer Inc, GlaxoSmithKline, Novartis AG, and Johnson & Johnson.

- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global gastrointestinal disorder therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to

- Align product portfolio to the markets with high growth potential

- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety

- Develop key strategic initiatives by understanding key focus areas of leading companies

- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

1 Executive Summary

2 Table of Contents
2.1 List of Tables
2.2 List of Figures

3 Global Gastrointestinal Disorder Therapeutics Market: Scope of Research
3.1 Introduction
3.2 GBI Research Report Guidance

4 Global Gastrointestinal Disorder Therapeutics Market: Market Characterization
4.1 Market Forecasts
4.2 Annual Cost of Treatment
4.3 Usage Patterns
4.3.1 Diseased Population
4.3.2 Treatment Seeking Population
4.3.3 Diagnosis Population
4.3.4 Prescription Population
4.3.5 Threapy Usage Patterns
4.3.6 Geographical Distribution

5 Global Gastrointestinal Disorder Therapeutics Market: US Market
5.1 Market Overview
5.2 Market Forecasts
5.3 Annual Cost of Treatment
5.4 Usage Patterns
5.4.1 Diseased Population
5.4.2 Treatment Seeking Population
5.4.3 Diagnosis Population
5.4.4 Prescription Population
5.4.5 Threapy Usage Patterns

6 Global Gastrointestinal Disorder Therapeutics Market: European Market
6.1 Market Overview
6.2 Market Forecasts
6.3 Annual Cost of Treatment
6.4 Usage Patterns
6.4.1 Diseased Population
6.4.2 Treatment Seeking Population
6.4.3 Diagnosis Population
6.4.4 Prescription Population
6.4.5 Therapy Usage Patterns

7 Global Gastrointestinal Disorder Therapeutics Market : Japan Market
7.1 Market Overview
7.2 Market Forecasts
7.3 Annual Cost of Treatment
7.4 Usage Patterns
7.4.1 Diseased Population
7.4.2 Treatment Seeking Population
7.4.3 Diagnosis Population
7.4.4 Prescription Population
7.4.5 Therapy Usage Patterns

8 Global Irritable Bowel Syndrome Therapeutics Market
8.1 Market Overview
8.2 Market Forecasts
8.3 Annual Cost of Treatment
8.4 Usage Patterns
8.4.1 Diseased Population
8.4.2 Treatment Seeking Population
8.4.3 Diagnosis Population
8.4.4 Prescription Population
8.4.5 Threapy Usage Patterns
8.5 Product Analysis
8.5.1 Lotronex (Alosetron)
8.5.2 Amitiza (Lubiprostone)
8.5.3 Colpermin (Peppermint Oil)
8.5.4 Bentyl (Dicyclomine hydrochloride)
8.6 Drug Pipeline Analysis

9 Global Ulcerative Colitis Therapeutics Market
9.1 Market Overview
9.2 Market Forecasts
9.3 Annual Cost of Treatment
9.4 Usage Patterns
9.4.1 Diseased Population
9.4.2 Treatment Seeking Population
9.4.3 Diagnosis Population
9.4.4 Prescription Population
9.4.5 Threapy Usage Patterns
9.5 Product Analysis
9.5.1 Asacol
9.5.2 Lialda
9.5.3 Pentasa
9.5.4 Apriso
9.5.5 Colazal
9.5.6 Remicade
9.5.7 Azulfidine
9.6 Drug Pipeline Analysis

10 Global GERD Therapeutics Market
10.1 Market Overview
10.2 Market Forecasts
10.3 Annual Cost of Treatment
10.4 Usage Patterns
10.4.1 Diseased Population
10.4.2 Treatment Seeking Population
10.4.3 Diagnosis Population
10.4.4 Prescription Population
10.4.5 Threapy Usage Patterns
10.5 Product Analysis
10.5.1 Nexium (esomeprazole)
10.5.2 Aciphex (rabeprazole sodium)
10.5.3 Prevacid (lansoprazole)
10.5.4 Prilosec (omeprazole)
10.5.5 Protonix (pantoprazole sodium)
10.5.6 Tagamet (cimetidine)
10.5.7 Pepcid (famotidine)
10.5.8 Zantac (ranitidine hydrochloride)
10.5.9 Axid (nizatidine)
10.6 Drug Pipeline Analysis

11 Global Crohn’s Disease Therapeutics Market
11.1 Market Overview
11.2 Market Forecasts
11.3 Annual Cost of Treatment
11.4 Usage Patterns
11.4.1 Diseased Population
11.4.2 Treatment Seeking Population
11.4.3 Diagnosis Population
11.4.4 Prescription Population
11.4.5 Therapy Usage Patterns
11.5 Product Analysis
11.5.1 Entocort EC (budenoside)
11.5.2 Humira (adalimumab)
11.5.3 Tysabri (natalizumab)
11.5.4 Remicade (infliximab)
11.5.5 Cimzia (cetrolizumab pegol)
11.6 Drug Pipeline Analysis

12 Global Gastrointestinal Disorder Therapeutics Market: Market Drivers and Restraints
12.1 Market Drivers
12.1.1 Steady Increase in the Elderly Population
12.1.2 Stable Increase in Incidence Rates for Gastrointestinal Disorders
12.1.3 Increase in Awareness Levels of Disease Progression and Etiology
12.2 Market Restraints
12.2.1 Entry of Generics Pose a Serious Problem for Primary Manufacturers
12.2.2 Presence of Serious Side Effects for Certain Classes of Therapeutic Drugs

13 Global Gastrointestinal Disorder Therapeutics Market : Key Market Trends

14 Global Gastrointestinal Disorder Therapeutics Market: Competitive Landscape
14.1 Overview
14.2 Competitive Profiling
14.3 GlaxoSmithKline, Inc
14.3.1 Overview
14.3.2 Business Description
14.4 AstraZeneca
14.4.1 Company Overview
14.4.2 AZD3355
14.5 Pfizer Incorporated
14.5.1 Overview
14.5.2 Business Description
14.6 Novartis Ag
14.6.1 Company Overview
14.6.2 Business Description
14.7 ChemoCentryx Inc
14.7.1 Overview
14.7.2 Gastrointestinal Disease Portfolio
14.7.3 Crohn’s Disease Product Portfolio
14.8 Bristol-Myers Squibb
14.8.1 Overview
14.8.2 Gastrointestinal Disease Portfolio
14.8.3 Crohn’s Disease Product Portfolio
14.9 Abbott Laboratories
14.9.1 Overview
14.9.2 Gastrointestinal Disease Portfolio
14.9.3 Crohn’s Disease Product Portfolio
14.10 XenoPort, Inc
14.10.1 Company Overview
14.10.2 XP19986
14.11 Addex Pharmaceuticals
14.11.1 Company Overview
14.11.2 ADX10059
14.12 Vecta Ltd. (Vecta)
14.12.1 Company Overview
14.12.2 Vecam
14.13 Ironwood Pharmaceuticals and Forest Laboratories
14.13.1 Company Overview
14.13.2 IBS pipeline portfolio
14.14 Tioga Pharmaceuticals
14.14.1 Company Overview
14.14.2 IBS Pipeline Porfolio
14.15 Alimentary Health Ltd & P & G
14.15.1 Company Overview
14.15.2 IBS Pipeline Portfolio
14.15.3 Bifantis (Bifidobacterium infantis 35624)
14.16 Lexicon
14.16.1 Company Overview
14.16.2 IBS pipeline portfolio
14.16.3 LX-103
14.17 Salix Pharmaceuticals
14.17.1 Overview
14.17.2 Business Description
14.17.3 IBS pipeline portfolio
Xifaxan (Rifaximin)
14.17.4 Ulcerative Colitis pipeline portfolio
14.18 Astellas Pharma
14.18.1 Overview
14.18.2 IBS Pipeline Portfolio

15 Gastrointestinal Disorder Therapeutics Market: Pipeline Analysis
15.1 Preclinical
15.2 Phase I
15.3 Pipeline II
15.4 Phase III
15.5 Promising Drugs under Clinical Development for Crohn’s Disease
15.5.1 Myoconda
15.5.2 Traficet-EN (CCX282)
15.5.3 MLN0002 (vedolizumab)
15.5.4 Orencia (abatacept)
15.5.5 ABT-874
15.5.6 Stelara
15.6 Promising Drugs under Clinical Development for Irritable Bowel Syndrome
15.6.1 Linaclotide (Linaclotide Acetate)
15.6.2 Asimadoline
15.6.3 Xifaxan (Rifaximin)
15.6.4 Bifantis (Bifidobacterium infantis 35624)
15.6.5 LX-103
15.6.6 YM060 (Ramosetron hydrochloride)
15.7 Promising Drugs under Clinical Development for GERD
15.7.1 XP19986
15.7.2 AZD3355
15.7.3 ADX10059
15.7.4 Vecam
15.8 Promising Drugs under Clinical Development for Ulcerative Colitis
15.8.1 Prograf (Tacrolimus)
15.8.2 Vedolizumab
15.8.3 Abatacept
15.8.4 Adalimumab
15.8.5 Golimumab

16 Global Gastrointestinal Disorder Therapeutics Market: Strategic Consolidations
16.1 Mergers and Acquisitions
16.1.1 Overview
16.1.2 GlaxoSmithKline Acquires AZ Tika Of AstraZeneca
16.1.3 ViroPharma Acquires Lev Pharmaceuticals
16.1.4 UCB Acquires Remaining Stake In Schwarz Pharma
16.1.5 Teva Pharmaceutical Acquires Bentley Pharmaceuticals
16.1.6 Gilead Sciences Acquires Nycomed Limited
16.2 Licensing Agreements
16.2.1 Overview

17 Global Gastrointestinal Disorder Therapeutics Market : Appendix
17.1 Market Definitions
17.2 Abbreviations
17.3 Research Methodology
17.3.1 Coverage
17.3.2 Secondary Research
17.3.3 Primary Research
17.3.4 Forecasts
17.3.5 Expert Panel Validation
17.4 Contact Us
17.5 Disclaimer

List of Tables:

Table 1: Gastrointestinal Disorder Therapeutics Market, Global, Revenue ($bn), 2001–2009
Table 2: Gastrointestinal Disorder Therapeutics Market, Global, Revenue ($bn), 2009–2016
Table 3: Gastrointestinal Disorder Therapeutics Market, Global, Annual Cost of Treatment, 2001–2009
Table 4: Gastrointestinal Disorder Therapeutics Market, Global, Annual Cost of Treatment, 2009–2016
Table 5: Gastrointestinal Disorder Therapeutics Market, Global, Diseased Population, 2001–2009
Table 6: Gastrointestinal Disorder Therapeutics Market, Global, Diseased Population, 2009–2016
Table 7: Gastrointestinal Disorder Therapeutics Market, Global, Treatment Seeking Population, 2001–2009
Table 8: Gastrointestinal Disorder Therapeutics Market, Global, Treatment Seeking Population, 2009–2016
Table 9: Gastrointestinal Disorder Therapeutics Market, Global, Diagnosis Population, 2001–2009
Table 10: Gastrointestinal Disorder Therapeutics Market, Global, Diagnosis Population, 2009–2016
Table 11: Gastrointestinal Disorder Therapeutics Market, Global, Prescription Population, 2001–2009
Table 12: Gastrointestinal Disorder Therapeutics Market, Global, Prescription Population, 2009–2016
Table 13: Gastrointestinal Disorder Therapeutics Market, Global, Usage Patterns, 2001–2009
Table 14: Gastrointestinal Disorder Therapeutics Market, Global, Usage Patterns, 2009–2016
Table 15: Gastrointestinal Disorder Therapeutics Market, The US, Revenue ($bn), 2001–2009
Table 16: Gastrointestinal Disorder Therapeutics Market, The US, Revenue ($bn), 2009–2016
Table 17: Gastrointestinal Disorder Therapeutics Market, The US, Annual Cost of Treatment , 2001–2009
Table 18: Gastrointestinal Disorder Therapeutics Market, The US, Annual Cost of Treatment, 2009–2016
Table 19: Gastrointestinal Disorder Therapeutics Market, The US, Diseased Population, 2001–2009
Table 20: Gastrointestinal Disorder Therapeutics Market, The US, Diseased Population, 2009–2016
Table 21: Gastrointestinal Disorder Therapeutics Market, The US, Treatment Seeking Population, 2001–2009
Table 22: Gastrointestinal Disorder Therapeutics Market, The US, Treatment Seeking Population, 2009–2016
Table 23: Gastrointestinal Disorder Therapeutics Market, The US, Diagnosis Population, 2001–2009
Table 24: Gastrointestinal Disorder Therapeutics Market, The US, Diagnosis Population, 2009–2016
Table 25: Gastrointestinal Disorder Therapeutics Market, The US, Prescription Population, 2001–2009
Table 26: Gastrointestinal Disorder Therapeutics Market, The US, Prescription Population, 2009–2016
Table 27: Gastrointestinal Disorder Therapeutics Market, The US, Usage Patterns, 2001–2009
Table 28: Gastrointestinal Disorder Therapeutics Market, The US, Usage Patterns, 2009–2016
Table 29: Gastrointestinal Disorder Therapeutics Market, Europe, Revenue ($bn), 2001–2009
Table 30: Gastrointestinal Disorder Therapeutics Market, Europe, Revenue ($bn), 2009–2016
Table 31: Gastrointestinal Disorder Therapeutics Market, Europe, Annual Cost of Treatment, 2001–2009
Table 32: Gastrointestinal Disorder Therapeutics Market, Europe, Annual Cost of Treatment, 2009–2016
Table 33: Gastrointestinal Disorder Therapeutics Market, Europe, Diseased Population, 2001–2009
Table 34: Gastrointestinal Disorder Therapeutics Market, Europe, Diseased Population, 2009–2016
Table 35: Gastrointestinal Disorder Therapeutics Market, Europe, Treatment Seeking Population, 2001–2009
Table 36: Gastrointestinal Disorder Therapeutics Market, Europe, Treatment Seeking Population, 2009–2016
Table 37: Gastrointestinal Disorder Therapeutics Market, Europe, Diagnosis Population, 2001–2009
Table 38: Gastrointestinal Disorder Therapeutics Market, Europe, Diagnosis Population, 2009–2016
Table 39: Gastrointestinal Disorder Therapeutics Market, Europe, Prescription Population, 2001–2009
Table 40: Gastrointestinal Disorder Therapeutics Market, Europe, Prescription Population, 2009–2016
Table 41: Gastrointestinal Disorder Therapeutics Market, Europe, Usage Patterns, 2001–2009
Table 42: Gastrointestinal Disorder Therapeutics Market, Europe, Usage Patterns, 2009–2016
Table 43: Gastrointestinal Disorder Therapeutics Market, Japan, Revenue ($bn), 2001–2009
Table 44: Gastrointestinal Disorder Therapeutics Market, Japan, Revenue ($bn), 2009–2016
Table 45: Gastrointestinal Disorder Therapeutics Market, Japan, Annual Cost of Treatment , 2001–2009
Table 46: Gastrointestinal Disorder Therapeutics Market, Japan, Annual Cost of Treatment, 2009–2016
Table 47: Gastrointestinal Disorder Therapeutics Market, Japan, Diseased Population, 2001–2009
Table 48: Gastrointestinal Disorder Therapeutics Market, Japan, Diseased Population, 2009–2016
Table 49: Gastrointestinal Disorder Therapeutics Market, Japan, Treatment Seeking Population, 2001–2009
Table 50: Gastrointestinal Disorder Therapeutics Market, Japan, Treatment Seeking Population, 2009–2016
Table 51: Gastrointestinal Disorder Therapeutics Market, Japan, Diagnosis Population, 2001–2009
Table 52: Gastrointestinal Disorder Therapeutics Market, Japan, Diagnosis Population, 2009–2016
Table 53: Gastrointestinal Disorder Therapeutics Market, Japan, Prescription Population, 2009–2016
Table 54: Gastrointestinal Disorder Therapeutics Market, Japan, Prescription Population, 2001–2009
Table 55: Gastrointestinal Disorder Therapeutics Market, Japan, Usage Patterns, 2001–2009
Table 56: Gastrointestinal Disorder Therapeutics Market, Japan, Usage Patterns, 2009–2016
Table 57: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue ($m), 2001–2009
Table 58: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue ($m), 2009–2016
Table 59: Irritable Bowel Syndrome Therapeutics Market, Global, Annual Cost of Treatment, 2001–2009
Table 60: Irritable Bowel Syndrome Therapeutics Market, Global, Annual Cost of Treatment, 2009–2016
Table 61: Irritable Bowel Syndrome Therapeutics Market, Global, Diseased Population, 2001–2009
Table 62: Irritable Bowel Syndrome Therapeutics Market, Global, Diseased Population, 2009–2016
Table 63: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Seeking Population, 2001–2009
Table 64: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Seeking Population, 2009–2016
Table 65: Irritable Bowel Syndrome Therapeutics Market, Global, Diagnosis Population, 2001–2009
Table 66: Irritable Bowel Syndrome Therapeutics Market, Global, Diagnosis Population, 2009–2016
Table 67: Irritable Bowel Syndrome Therapeutics Market, Global, Prescription Population, 2001–2009
Table 68: Irritable Bowel Syndrome Therapeutics Market, Global, Prescription Population, 2009–2016
Table 69: Irritable Bowel Syndrome Therapeutics Market, Global, Usage Patterns, 2001–2009
Table 70: Irritable Bowel Syndrome Therapeutics Market, Global, Usage Patterns, 2009–2016
Table 71: Ulcerative Colitis Therapeutics Market, Global, Revenue ($m), 2001–2009
Table 72: Ulcerative Colitis Therapeutics Market, Global, Revenue ($m), 2009–2016
Table 73: Ulcerative Colitis Therapeutics Market, Global, Annual Cost of Treatment , 2001–2009
Table 74: Ulcerative Colitis Therapeutics Market, Global, Annual Cost of Treatment , 2009–2016
Table 75: Ulcerative Colitis Therapeutics Market, Global, Diseased Population, 2001–2009
Table 76: Ulcerative Colitis Therapeutics Market, Global, Diseased Population, 2009–2016
Table 77: Ulcerative Colitis Therapeutics Market, Global, Treatment Seeking Population, 2001–2009
Table 78: Ulcerative Colitis Therapeutics Market, Global, Treatment Seeking Population, 2009–2016
Table 79: Ulcerative Colitis Therapeutics Market, Global, Diagnosis Population, 2001–2009
Table 80: Ulcerative Colitis Therapeutics Market, Global, Diagnosis Population, 2009–2016
Table 81: Ulcerative Colitis Therapeutics Market, Global, Prescription Population, 2001–2009
Table 82: Ulcerative Colitis Therapeutics Market, Global, Prescription Population, 2009–2016
Table 83: Ulcerative Colitis Therapeutics Market, Global, Usage Patterns, 2001–2009
Table 84: Ulcerative Colitis Therapeutics Market, Global, Usage Patterns, 2009–2016
Table 85: GERD Therapeutics Market, Global, Revenue ($m), 2001–2009
Table 86: GERD Therapeutics Market, Global, Revenue ($m), 2009–2016
Table 87: GERD Therapeutics Market, Global, Annual Cost of Treatment, 2001–2009
Table 88: GERD Therapeutics Market, Global, Annual Cost of Treatment, 2009–2016
Table 89: GERD Therapeutics Market, Global, Diseased Population, 2001–2009
Table 90: GERD Therapeutics Market, Global, Diseased Population, 2009–2016
Table 91: GERD Therapeutics Market, Global, Treatment Seeking Population, 2001–2009
Table 92: GERD Therapeutics Market, Global, Treatment Seeking Population, 2009–2016
Table 93: GERD Therapeutics Market, Global, Diagnosis Population, 2001–2009
Table 94: GERD Therapeutics Market, Global, Diagnosis Population, 2009–2016
Table 95: GERD Therapeutics Market, Global, Prescription Population, 2001–2009
Table 96: GERD Therapeutics Market, Global, Prescription Population, 2009–2016
Table 97: GERD Therapeutics Market, Global, Usage Patterns, 2001–2009
Table 98: GERD Therapeutics Market, Global, Usage Patterns, 2009–2016
Table 99: Crohn’s Disease Therapeutics Market, Global, Revenue ($m), 2001–2009
Table 100: Crohn’s Disease Therapeutics Market, Global, Revenue ($m), 2009–2016
Table 101:Crohn’s Disease Therapeutics Market, Global, Annual Cost of Treatment, 2001–2009
Table 102:Crohn’s Disease Therapeutics Market, Global, Annual Cost of Treatment, 2009–2016
Table 103: Crohn’s Disease Therapeutics Market, Global, Diseased Population, 2001–2009
Table 104: Crohn’s Disease Therapeutics Market, Global, Diseased Population, 2009–2016
Table 105: Crohn’s Disease Therapeutics Market, Global, Treatment Seeking Population, 2001–2009
Table 106:Crohn’s Disease Therapeutics Market, Global, Treatment Seeking Population, 2009–2016
Table 107:Crohn’s Disease Therapeutics Market, Global, Diagnosis Population, 2001–2009
Table 108:Crohn’s Disease Therapeutics Market, Global, Diagnosis Population, 2009–2016
Table 109:Crohn’s Disease Therapeutics Market, Global, Prescription Population, 2001–2009
Table 110:Crohn’s Disease Therapeutics Market, Global, Prescription Population, 2009–2016
Table 111:Crohn’s Disease Therapeutics Market, Global, Usage Patterns, 2001–2009
Table 112:Crohn’s Disease Therapeutics Market, Global, Usage Patterns, 2009–2016
Table 113: Gastrointestinal Disorder Therapeutics Market, Global, Market Drivers, 2009
Table 114: Gastrointestinal Disorder Therapeutics Market, Global, Market Restraints, 2009
Table 115: GlaxoSmithKline – Ulcerative Colitis Pipeline, 2009
Table 116: Pfizer – Ulcerative Colitis Pipeline, 2009
Table 117: ChemoCentryx Inc. – Autoimmune and Gastrointestinal Disease Pipeline Products, 2009
Table 118: Bristol-Myers Squibb – Gastrointestinal Pipeline Products, 2009
Table 119: Abbott Laboratories – Gastrointestinal Marketed Products, 2009
Table 120: Abbott Laboratories – Gastrointestinal Pipeline Products, 2009
Table 121: Ironwood Pharmaceuticals– IBS pipeline products, 2010
Table 122: Tioga Pharmaceuticals – IBS Pipeline Products, 2010
Table 123: Alimentary Health Ltd & P & G - IBS pipeline products, 2010
Table 124: Lexicon - IBS pipeline portfolio, 2010
Table 125: Salix Pharmaceutical - IBS Pipeline Portfolio, 2010
Table 126: Salix Pharmaceuticals – Ulcerative Colitis Pipeline, 2009
Table 127: Astellas Pharma - IBS Pipeline Portfolio, 2010
Table 128:Gastrointestinal Disorder Therapeutics Market, Global, Preclinical Pipeline, 2009
Table 129:Gastrointestinal Disorder Therapeutics Market, Global, Phase I Pipeline, 2009
Table 130:Gastrointestinal Disorder Therapeutics Market, Global, Phase II Pipeline, 2009
Table 131:Gastrointestinal Disorder Therapeutics Market, Global, Phase III Pipeline, 2009

List of Figures:

Figure 1: Gastrointestinal Disorder Therapeutics Market, Global, Pipeline by Phase (%), 2009
Figure 2: Gastrointestinal Disorder Therapeutics Market, Global, Licensing Agreements Split by Phase (%), 1998-2010
Figure 3: Gastrointestinal Disorder Therapeutics Market, Global, Revenue ($m), 2001-2016
Figure 4: Gastrointestinal Disorder Therapeutics Market, Global, Annual Cost of Treatment, 2001–2016
Figure 5: Gastrointestinal Disorder Therapeutics Market, Global, Diseased Population, 2001-2016
Figure 6: Gastrointestinal Disorder Therapeutics Market, Global, Treatment Seeking Population, 2001-2016
Figure 7: Gastrointestinal Disorder Therapeutics Market, Global, Diagnosis Population, 2001-2016
Figure 8: Gastrointestinal Disorder Therapeutics Market, Global, Prescription Population, 2001-2016
Figure 9: Gastrointestinal Disorder Therapeutics Market, Global, Usage Patterns, 2001-2016
Figure 10: Gastrointestinal Disorder Therapeutics Market, Global, Geographical Distribution of Revenues ($bn), 2001-2016
Figure 11: Gastrointestinal Disorder Therapeutics Market, The US, Revenue ($m), 2001-2016
Figure 12: Gastrointestinal Disorder Therapeutics Market, The US, Annual Cost of Treatment, 2001-2016
Figure 13: Gastrointestinal Disorder Therapeutics Market, The US, Diseased Population, 2001-2016
Figure 14: Gastrointestinal Disorder Therapeutics Market, The US, Treatment Seeking Population, 2001-2016
Figure 15: Gastrointestinal Disorder Therapeutics Market, The US, Diagnosis Population, 2001-2016
Figure 16: Gastrointestinal Disorder Therapeutics Market, The US, Prescription Population, 2001-2016
Figure 17: Gastrointestinal Disorder Therapeutics Market, The US, Usage Patterns, 2001-2016
Figure 18: Gastrointestinal Disorder Therapeutics Market, Europe, Revenue ($m), 2001-2016
Figure 19: Gastrointestinal Disorder Therapeutics Market, Europe, Annual Cost of Treatment, 2001-2016
Figure 20: Gastrointestinal Disorder Therapeutics Market, Europe, Diseased Population, 2001-2016
Figure 21: Gastrointestinal Disorder Therapeutics Market, Europe, Treatment Seeking Population, 2001-2016
Figure 22: Gastrointestinal Disorder Therapeutics Market, Europe, Diagnosis Population, 2001-2016
Figure 23: Gastrointestinal Disorder Therapeutics Market, Europe, Prescription Population, 2001-2016
Figure 24: Gastrointestinal Disorder Therapeutics Market, Europe, Usage Patterns, 2001-2016
Figure 25: Gastrointestinal Disorder Therapeutics Market, Japan, Revenue ($bn), 2001-2016
Figure 26: Gastrointestinal Disorder Therapeutics Market, Japan, Annual Cost of Treatment, 2001-2016
Figure 27: Gastrointestinal Disorder Therapeutics Market, Japan, Diseased Population, 2001-2016
Figure 28: Gastrointestinal Disorder Therapeutics Market, Japan, Treatment Seeking Population, 2001-2016
Figure 29: Gastrointestinal Disorder Therapeutics Market, Japan, Diagnosis Population, 2001-2016
Figure 30: Gastrointestinal Disorder Therapeutics Market, Japan, Prescription Population, 2001-2016
Figure 31: Gastrointestinal Disorder Therapeutics Market, Japan, Usage Patterns, 2001-2016
Figure 32: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue ($m), 2001-2016
Figure 33: Irritable Bowel Syndrome Therapeutics Market, Global, Annual Cost of Treatment, 2001-2016
Figure 34: Irritable Bowel Syndrome Therapeutics Market, Global, Diseased Population, 2001-2016
Figure 35: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Seeking Population, 2001-2016
Figure 36: Irritable Bowel Syndrome Therapeutics Market, Global, Diagnosis Population, 2001-2016
Figure 37: Irritable Bowel Syndrome Therapeutics Market, Global, Prescription Population, 2001-2016
Figure 38: Irritable Bowel Syndrome Therapeutics Market, Global, Usage Patterns, 2001-2016
Figure 39: Irritable Bowel Syndrome Therapeutics Market, Global, Pipeline by Phases, 2009
Figure 40: Ulcerative Colitis Therapeutics Market, Global, Revenue ($m), 2001-2016
Figure 41: Ulcerative Colitis Therapeutics Market, Global, Annual Cost of Treatment, 2001-2016
Figure 42: Ulcerative Colitis Therapeutics Market, Global, Diseased Population, 2001-2016
Figure 43: Ulcerative Colitis Therapeutics Market, Global, Treatment Seeking Population, 2001-2016
Figure 44: Ulcerative Colitis Therapeutics Market, Global, Diagnosis Population, 2001-2016
Figure 45: Ulcerative Colitis Therapeutics Market, Global, Prescription Population, 2001-2016
Figure 46: Ulcerative Colitis Therapeutics Market, Global, Usage Patterns, 2001-2016
Figure 47: Ulcerative Colitis Therapeutics Market, Global, Pipeline by Phases, 2009
Figure 48: GERD Therapeutics Market, Global, Revenue ($m), 2001-2016
Figure 49: GERD Therapeutics Market, Global, Annual Cost of Treatment, 2001-2016
Figure 50: GERD Therapeutics Market, Global, Diseased Population, 2001-2016
Figure 51: GERD Therapeutics Market, Global, Treatment Seeking Population, 2001-2016
Figure 52: GERD Therapeutics Market, Global, Diagnosis Population, 2001-2016
Figure 53: GERD Therapeutics Market, Global, Prescription Population, 2001-2016
Figure 54: GERD Therapeutics Market, Global, Usage Patterns, 2001-2016
Figure 55: GERD Therapeutics Market, Global, Pipeline by Phases, 2009
Figure 56: Crohn’s’s Disease Therapeutics Market, Global, Revenue ($m), 2001-2016
Figure 57: Crohn’s’s Disease Therapeutics Market, Global, Annual Cost of Treatment, 2001-2016
Figure 58: Crohn’s’s Disease Therapeutics Market, Global, Diseased Population, 2001-2016
Figure 59: Crohn’s’s Disease Therapeutics Market, Global, Treatment Seeking Population, 2001-2016
Figure 60: Crohn’s’s Disease Therapeutics Market, Global, Diagnosis Population, 2001-2016
Figure 61: Crohn’s’s Disease Therapeutics Market, Global, Prescription Population, 2001-2016
Figure 62: Crohn’s’s Disease Therapeutics Market, Global, Usage Patterns, 2001-2016
Figure 63: Crohn’s Disease Therapeutics Market, Global, Usage Patterns, 2009–2016
Figure 64: Gastrointestinal Disorder Therapeutics Market, Global, Market Indicators, 2009
Figure 65: Gastrointestinal Disorder Therapeutics Market, Global, Key Market Events, 2009-2015
Figure 66: Gastrointestinal Disorder Therapeutics Market, Global, Key Market Events, 2009-2016
Figure 67: Gastrointestinal Disorder Therapeutics Market, Global, Pipeline by Phase, 2009
Figure 68: Gastrointestinal Disorder Therapeutics Market, Global, Pipeline by Indication, 2009
Figure 69: Gastrointestinal Disorder Therapeutics Market, Global, Preclinical Pipeline by Indication, 2009
Figure 70: Gastrointestinal Disorder Therapeutics Market, Global, Phase I Pipeline by Indication, 2009
Figure 71: Gastrointestinal Disorder Therapeutics Market, Global, Phase II Pipeline by Indication, 2009
Figure 72: Gastrointestinal Disorder Therapeutics Market, Global, Phase III Pipeline by Indication, 2009
Figure 73: Gastrointestinal Disorder Therapeutics Market, Global, Licensing Agreements Split by Phases, 1998-2010
Figure 74: Gastrointestinal Disorder Therapeutics Market, Global, Licensing Agreements Split by Indication, 1998-2010
Figure 75: Gastrointestinal Disorder Therapeutics Market, Global, Licensing Agreements Split by Approved Date, 1998 - 2010
Figure 76: GBI Research Methodology, 2010
Figure 77: GBI Research Market Forecasting Methodology, 2010

“Gastrointestinal Disorder Therapeutics to 2016 – High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets” provides in-depth analysis of the unmet needs, drivers and barriers that affect the global gastrointestinal disorder therapeutics market. The report analyzes the markets for gastrointestinal disorder in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

The Irritable Bowel Syndrome Market is a Fast Growing Market with Strong Pipeline Drugs with High Safety and Efficacy Profiles

The global gastrointestinal disorder therapeutics market generated approximately $25.6 billion in 2009. The market is anticipated to reach revenues of approximately $17.3 billion by 2016 after declining at a CAGR of -5.4% between 2009 and 2016. In 2010, the market is forecast to reach revenues of about $24.5 billion. From 2001, the market grew at a CAGR of 4.4% to reach $25.6 billion in 2009. The decline in the market is due to major drugs going off-patent in the Gastroesophageal Reflux Disease (GERD) market. Irritable bowel syndrome was one of the fastest growing segments. This growth is primarily attributed to a strong pipeline with more emerging therapies. The expected new drug launches will be priced highly and will capture a major share of the prescriptions. Hence the irritable bowel syndrome market is expected to reap large revenues with the increased uptake of these new drugs and the increased awareness of the disease in patients leading to increased treatment seeking rates at the early stages of the disease.

Increasing R&D in Gastrointestinal Disorders Segment Boosts a Strong Clinical Pipeline

In the gastrointestinal sector, most of the companies coordinate their R&D activities in order to constantly expand their product pipelines with innovative drugs. Although there is a consistent and continuous threat from generics and other alternatives, companies in the gastrointestinal disorders sector are not reluctant to invest in R&D and are focused on offering new products to the market. There are more than 240 drugs in the gastrointestinal disorders pipeline. Phase II has the most pipeline drugs, accounting for 48% of the pipeline, while the Phase III, Phase I and preclinical stages of the pipeline accounted for 24%, 18% and 10%, respectively.

- GlaxoSmithKline, Inc
- AstraZeneca
- Pfizer Incorporated
- Novartis Ag
- ChemoCentryx Inc.
- Bristol-Myers Squibb
- Abbott Laboratories
- XenoPort, Inc.
- Addex Pharmaceuticals
- Vecta Ltd. (Vecta)
- Ironwood Pharmaceuticals and Forest Laboratories
- Tioga Pharmaceuticals
- Alimentary Health Ltd & P & G
- Lexicon
- Salix Pharmaceuticals
- Astellas Pharma

Product Samples

A sample for this product is available. Please Login/Register to download this sample.

Customers who bought this item also bought

• Probiotics - Global Strategic Business Report
• RNA Interference (RNAi) - Global Strategic Business Report
• Proteomics - Global Strategic Business Report
• Stem Cell Research - Global Business Strategic Report
• Gene Amplification Technologies - Global Strategic Business Report
• Biophotonics - Global Strategic Business Report
• Biotechnology Instrumentation - Global Strategic Business Report
• Global Biopharmaceutical Market Report & Forecast (2012-2017)
• Agricultural Biotechnology - Global Strategic Business Report
• Biotechnology Reagents - Global Strategic Business Report